Fig. 3From: Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibitionPotential mechanisms of HDAC2i acts as sensitizer for PD-1/PD-L1 blockade therapy. HDAC2i can suppress the PD-L1 nuclear translocation regulated by regulating HIP1R, Vimentin and KPNAS. Moreover, HDAC2i can also inhibit the process of IFNγ-induced PD-L1 expression regulated by STAT1, BRD4, H3K27, etc.Back to article page